CRISPR Therapeutics AG - Common Stock (CRSP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRSP on Nasdaq
Shares outstanding
95,714,968
Price per share
$55.52
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
76,454,418
Total reported value
$4,010,503,102
% of total 13F portfolios
0%
Share change
+866,476
Value change
+$35,191,052
Number of holders
467
Price from insider filings
$55.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CRISPR Therapeutics AG - Common Stock (CRSP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 11% -9.1% $634,293,720 -$24,525,854 9,786,973 -3.7% ARK Investment Management LLC 30 Sep 2025
ORBIS INVESTMENT MANAGEMENT LTD 6.2% +12% $328,168,338 +$53,099,226 5,934,328 +19% ORBIS INVESTMENT MANAGEMENT LTD 31 Dec 2025
BlackRock, Inc. 6.9% $288,553,541 5,932,433 BlackRock, Inc. 30 Jun 2025
Capital International Investors 1.2% -89% $62,235,477 -$269,926,929 1,186,794 -81% Capital International Investors 30 Jan 2026

As of 31 Dec 2025, 467 institutional investors reported holding 76,454,418 shares of CRISPR Therapeutics AG - Common Stock (CRSP). This represents 80% of the company’s total 95,714,968 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CRISPR Therapeutics AG - Common Stock (CRSP) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARK Investment Management LLC 11% 10,522,057 +7.5% 3.7% $551,776,677
BlackRock, Inc. 7.8% 7,508,178 +6.5% 0.01% $393,728,856
Orbis Allan Gray Ltd 6.2% 5,950,145 +19% 1.3% $312,025,603
Capital International Investors 6.2% 5,892,745 +4.3% 0.05% $309,015,548
STATE STREET CORP 3.9% 3,753,440 -6.3% 0.01% $196,830,394
T. Rowe Price Investment Management, Inc. 3.4% 3,226,595 -1.7% 0.11% $169,203,000
GSK plc 3.4% 3,220,627 0% 21% $168,889,680
UBS Group AG 2.6% 2,524,144 +7.9% 0.03% $132,366,111
VANGUARD GROUP INC 2.4% 2,268,394 -4.1% 0% $118,954,581
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,249,223 +5% 0.01% $117,970,852
SR One Capital Management, LP 2.1% 2,038,763 0% 15% $106,912,732
Sumitomo Mitsui Trust Group, Inc. 2% 1,958,111 -9.5% 0.06% $102,683,341
Amova Asset Management Americas, Inc. 2% 1,958,111 -9.5% 1.2% $102,605,016
FMR LLC 2% 1,953,957 +3.6% 0.01% $102,465,517
EcoR1 Capital, LLC 1.5% 1,389,276 0% 3.3% $72,853,633
BANK OF AMERICA CORP /DE/ 1.1% 1,096,887 -2.4% 0% $57,520,761
NEA Management Company, LLC 1.1% 1,058,570 0% 2.8% $55,511,411
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 1,030,182 +4.5% 0.01% $54,022,744
DIMENSIONAL FUND ADVISORS LP 0.95% 907,107 +3.4% 0.01% $47,572,612
LOOMIS SAYLES & CO L P 0.94% 899,331 -1.1% 0.06% $47,160,918
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.89% 853,971 +4.9% 0.06% $44,782,239
NORTHERN TRUST CORP 0.79% 755,105 -3.2% 0.01% $39,597,706
MORGAN STANLEY 0.7% 667,060 -52% 0% $34,980,655
Squarepoint Ops LLC 0.61% 581,108 0.06% $30,473,304
JPMORGAN CHASE & CO 0.57% 542,954 -8.5% 0% $28,472,508

Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 76,454,418 $4,010,503,102 +$35,191,052 $52.44 467
2025 Q3 72,232,011 $4,681,195,868 +$29,481,399 $64.81 434
2025 Q2 72,314,703 $3,517,677,257 +$428,897,837 $48.64 426
2025 Q1 64,129,300 $2,183,568,653 -$16,834,672 $34.03 388
2024 Q4 64,443,699 $2,536,549,693 +$179,624,639 $39.36 398
2024 Q3 59,826,628 $2,811,325,020 +$6,501,203 $46.98 407
2024 Q2 59,510,276 $3,214,159,736 +$50,043,500 $54.01 439
2024 Q1 57,288,998 $3,904,937,558 +$217,314,654 $68.16 469
2023 Q4 55,520,285 $3,475,779,179 +$42,550,297 $62.60 465
2023 Q3 54,993,134 $2,496,662,136 -$1,898,845 $45.39 400
2023 Q2 54,718,539 $3,071,120,295 -$80,853,798 $56.14 409
2023 Q1 56,199,828 $2,540,792,585 +$38,754,979 $45.23 375
2022 Q4 55,494,852 $2,255,613,450 -$74,822,214 $40.65 386
2022 Q3 56,683,321 $3,701,432,142 -$78,744,860 $65.35 410
2022 Q2 55,502,675 $3,344,489,851 +$271,662,077 $60.77 404
2022 Q1 49,481,600 $3,107,777,604 +$483,746,495 $62.77 415
2021 Q4 42,884,873 $3,253,105,466 +$73,035,179 $75.78 425
2021 Q3 40,405,115 $4,522,264,525 -$41,114,506 $111.93 458
2021 Q2 40,533,549 $6,560,272,742 -$153,120,996 $161.89 484
2021 Q1 42,643,720 $5,195,793,257 -$576,803,869 $121.85 431
2020 Q4 47,170,730 $7,222,892,447 +$35,286,644 $153.11 397
2020 Q3 47,858,309 $4,002,814,216 +$723,322,979 $83.64 300
2020 Q2 38,277,395 $2,809,424,935 +$279,188,892 $73.49 263
2020 Q1 35,534,767 $1,506,022,854 +$153,360,658 $42.41 244
2019 Q4 31,537,408 $1,920,718,365 +$255,276,153 $60.90 248
2019 Q3 27,534,073 $1,131,426,201 -$8,297,966 $40.99 176
2019 Q2 27,401,117 $1,290,347,942 +$107,556,651 $47.10 176
2019 Q1 26,007,044 $928,966,936 +$146,098,285 $35.72 163
2018 Q4 22,084,355 $630,914,836 -$57,784,767 $28.57 151
2018 Q3 22,857,503 $1,013,718,783 +$176,760,080 $44.35 171
2018 Q2 18,496,060 $1,086,865,478 -$651,038 $58.76 171
2018 Q1 18,718,531 $855,401,603 +$303,959,521 $45.71 132
2017 Q4 12,499,892 $293,264,477 +$61,797,532 $23.48 82
2017 Q3 10,055,642 $179,590,160 +$6,177,091 $17.87 61
2017 Q2 9,694,198 $155,107,419 -$4,334,397 $16.02 36
2017 Q1 9,693,488 $210,826,092 -$2,609,245 $21.77 36
2016 Q4 9,833,888 $197,779,000 +$197,766,000 $20.26 26
2016 Q2 0 $0 -$1,000 $55.52 0
2016 Q1 40 $1,000 $25.00 1